Schelter BO et al., 2019: Population pharmacokinetic re-analysis of the two phase 3 LMTM trials (1,162 of 1,686 patients with plasma samples) showing steep concentration-response relationships at the 8 mg/day dose and no additional benefit at the 4-21 ng/ml levels produced by high doses. The paper states that TauRx wholly sponsored the study and led its design, conduct, interpretation and drafting.
The study was wholly sponsored by TauRx Therapeutics Ltd. (Singapore). The funder of the study took the lead in study design, undertaking the study, data interpretation, and initial drafting of the report.
Schelter BO et al., 2019: Population pharmacokinetic re-analysis of the two phase 3 LMTM trials (1,162 of 1,686 patients with plasma samples) showing steep concentration-response relationships at the 8 mg/day dose and no additional benefit at the 4-21 ng/ml levels produced by high doses. The paper states that TauRx wholly sponsored the study and led its design, conduct, interpretation and drafting. Study type: controlled study.
